Liu Shuang, Watanabe Shohei, Shudou Masachika, Kuno Miyuki, Miura Hiromasa, Maeyama Kazutaka
Department of Pharmacology, Ehime University Graduate School of Medicine, Ehime, Japan.
1] Department of Bone and Joint Surgery, Ehime University Graduate School of Medicine, Ehime, Japan [2] Community Health Care Organization Uwajima Hospital, Ehime, Japan.
Immunol Cell Biol. 2014 Oct;92(9):752-60. doi: 10.1038/icb.2014.45. Epub 2014 Jun 17.
The regulated control of Ca(2+) influx is essential for the activation and function of the adaptive immune response, as Ca(2+) is a key regulator of important transcription factors. To determine whether Ca(2+) release-activated Ca(2+) (CRAC) channels contribute to the abnormal behaviour of T cells in patients with rheumatoid arthritis (RA), we performed a cross-sectional study to characterize the expression and functional status of CRACM1 channels in RA patients. Peripheral blood was obtained from 50 RA patients, 50 osteoarthritis (OA) patients and healthy donors. We measured Ca(2+) influx and CRAC currents in naïve and memory CD4(+) T cells. CRACM1 expression was evaluated in T cells from each of the three groups. These cells were further characterized by flow cytometric analysis of interleukin-4 (IL-4), IL-17, interferon-γ and tumour necrosis factor-α. These cytokines were also measured in naïve CD4(+) T cells following the lentivirus-mediated silencing of CRACM1.There was a significant positive correlation between Ca(2+) influx in naïve T cells and RA activity. Functionally aberrant naïve CD4(+) T cells from patients with active RA showed the different cytokine release pattern and exhibited increased Ca(2+) influx as well as increased CRACM1 protein expression and function. Specific lentiviral-induced gene silencing of CRACM1 reversed the alterations in T-cell cytokine production. The data presented here indicate that an upregulation of CRACM1 expression and function may be responsible for the abnormal cytokine release of naïve CD4(+) T cells in RA patients. CRACM1 might therefore represent a new molecular target for RA therapies.
Ca(2+)内流的调控对于适应性免疫反应的激活和功能至关重要,因为Ca(2+)是重要转录因子的关键调节因子。为了确定Ca(2+)释放激活的Ca(2+)(CRAC)通道是否导致类风湿性关节炎(RA)患者T细胞的异常行为,我们进行了一项横断面研究,以表征RA患者中CRACM1通道的表达和功能状态。从50名RA患者、50名骨关节炎(OA)患者和健康供体中获取外周血。我们测量了初始和记忆CD4(+) T细胞中的Ca(2+)内流和CRAC电流。评估了三组中每组T细胞的CRACM1表达。通过白细胞介素-4(IL-4)、IL-17、干扰素-γ和肿瘤坏死因子-α的流式细胞术分析对这些细胞进行了进一步表征。在慢病毒介导的CRACM1沉默后,也在初始CD4(+) T细胞中测量了这些细胞因子。初始T细胞中的Ca(2+)内流与RA活动之间存在显著正相关。来自活动性RA患者的功能异常的初始CD4(+) T细胞表现出不同的细胞因子释放模式,并表现出增加 的Ca(2+)内流以及增加的CRACM1蛋白表达和功能。CRACM特异性慢病毒诱导的基因沉默逆转了T细胞细胞因子产生的改变。此处提供的数据表明,CRACM1表达和功能的上调可能是RA患者初始CD4(+) T细胞异常细胞因子释放的原因。因此,CRACM1可能代表RA治疗的新分子靶点。